Aclarion, Inc. Provides 2025 Update and 2026 Outlook
January 08, 2026 - by Gerry Griffith
Aclarion, Inc. (Nasdaq: ACON), a healthcare technology company leveraging biomarkers and AI to address chronic low back pain, shared its 2025 achievements and 2026 goals.
2025 Highlights:
- Growth: Nociscan scan volumes rose 69% year-over-year, with Q4 2025 seeing a 114% increase.
- Expansion: Added 9 imaging centers and 22 physician users, bolstered by key hires in the U.S. and UK.
- Clinical Evidence: Published studies demonstrated Nociscan’s cost-effectiveness and clinical utility, saving $1,712 per patient and improving surgical success rates by 10%.
- Financial Strength: Ended 2025 with $12M in cash, no debt, and a cash runway into 2027.
2026 Goals:
- Enroll 25% of patients in the CLARITY trial by Q2, with interim data expected in Q3.
- Launch Nociscan software version 2.8 in Q1 to enhance clinical scalability.
- Expand global market size by 30% through partnerships with MRI manufacturers.
- Collaborate with U.S. payers to broaden reimbursement coverage.
CEO Brent Ness emphasized the company’s focus on clinical validation, strategic partnerships, and long-term value creation for patients, providers, and shareholders.
For more information, visit www.aclarion.com.
